As shown in Figure 4C and 4D, the clinical score was decreased and the development of arthritis was strikingly delayed in the siRNA IL-17R OE-MSCs group, whereas the OE-MSCs presented relative worse therapeutic effect under the environment with high concentration of IL-17. This evidence concerns the gene IL17A and arthritic joint disease.